Repairing the parkinsonian brain with neurotrophic factors

Trends in Neurosciences

Volumn 34, Issue 2, 2011, Pages 88-100

  Aron, Liviu ^a   Klein, Rüdiger ^a  

^a MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CARDIOTROPHIN 1; CILIARY NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MICROSPHERE; NEUROTROPHIC FACTOR; NEUROTROPHIN 3; NEUROTROPHIN 4; NEURTURIN; ONCOSTATIN M; RASAGILINE;

ADENO ASSOCIATED VIRUS; CELL ENCAPSULATION; DOPAMINERGIC NERVE CELL; DRUG DELIVERY SYSTEM; ELECTRIC SHOCK; HEADACHE; HUMAN; LENTIVIRINAE; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR;

ANIMALS; BRAIN; CLINICAL TRIALS AS TOPIC; DOPAMINE; HUMANS; NERVE GROWTH FACTORS; NERVE REGENERATION; NEURODEGENERATIVE DISEASES; NEURONS; PARKINSON DISEASE; SIGNAL TRANSDUCTION;

EID: 79551611535     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2010.11.001     Document Type: Review

References (118)

1. Dawson T.M., et al. Genetic animal models of Parkinson's disease. Neuron 2010, 66:646-661.
2. Obeso J.A., et al. Missing pieces in the Parkinson's disease puzzle. Nat. Med. 2010, 16:653-661.
3. Lin L.F., et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
4. Airaksinen M.S., Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 2002, 3:383-394.
5. Paratcha G., Ledda F. GDNF and GFRalpha: a versatile molecular complex for developing neurons. Trends Neurosci. 2008, 31:384-391.
6. Bespalov M.M., Saarma M. GDNF family receptor complexes are emerging drug targets. Trends Pharmacol. Sci. 2007, 28:68-74.
7. Ibanez C.F. Beyond the cell surface: new mechanisms of receptor function. Biochem. Biophys. Res. Commun. 2010, 396:24-27.
8. Pozas E., Ibanez C.F. GDNF and GFRalpha1 promote differentiation and tangential migration of cortical GABAergic neurons. Neuron 2005, 45:701-713.
9. Ledda F., et al. GDNF and GFRalpha1 promote formation of neuronal synapses by ligand-induced cell adhesion. Nat. Neurosci. 2007, 10:293-300.
10. Boger H.A., et al. A partial GDNF depletion leads to earlier age-related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra. Exp. Neurol. 2006, 202:336-347.
11. Zaman V., et al. The nigrostriatal dopamine system of aging GFRalpha-1 heterozygous mice: neurochemistry, morphology and behavior. Eur. J. Neurosci. 2008, 28:1557-1568.
12. Mijatovic J., et al. Constitutive Ret activity in knock-in multiple endocrine neoplasia type B mice induces profound elevation of brain dopamine concentration via enhanced synthesis and increases the number of TH-positive cells in the substantia nigra. J. Neurosci. 2007, 27:4799-4809.
13. Pascual A., et al. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat. Neurosci. 2008, 11:755-761.
14. Jain S., et al. RET is dispensable for maintenance of midbrain dopaminergic neurons in adult mice. J. Neurosci. 2006, 26:11230-11238.
15. Kramer E.R., et al. Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol. 2007, 5:e39.
16. Yu L.Y., et al. Death receptors and caspases but not mitochondria are activated in the GDNF- or BDNF-deprived dopaminergic neurons. J. Neurosci. 2008, 28:7467-7475.
17. Pierchala B.A., et al. Glial cell line-derived neurotrophic factor-dependent recruitment of Ret into lipid rafts enhances signaling by partitioning Ret from proteasome-dependent degradation. J. Neurosci. 2006, 26:2777-2787.
18. Tsui C.C., Pierchala B.A. The differential axonal degradation of Ret accounts for cell-type-specific function of glial cell line-derived neurotrophic factor as a retrograde survival factor. J. Neurosci. 2010, 30:5149-5158.
19. Ledda F., et al. Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J. Neurosci. 2008, 28:39-49.
20. Vieira P., et al. Internalization of glial cell-derived neurotrophic factor receptor GFR alpha 1 in the absence of the ret tyrosine kinase coreceptor. Cell Mol. Neurobiol. 2003, 23:43-55.
21. Lindholm P., et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007, 448:73-77.
22. Petrova P., et al. MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J. Mol. Neurosci. 2003, 20:173-188.
23. Lindholm P., Saarma M. Novel CDNF/MANF family of neurotrophic factors. Dev. Neurobiol. 2010, 70:360-371.
24. Palgi M., et al. Evidence that DmMANF is an invertebrate neurotrophic factor supporting dopaminergic neurons. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2429-2434.
25. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
26. Andressoo J.O., Saarma M. Signalling mechanisms underlying development and maintenance of dopamine neurons. Curr. Opin. Neurobiol. 2008, 18:297-306.
27. Evans J.R., Barker R.A. Neurotrophic factors as a therapeutic target for Parkinson's disease. Expert Opin. Ther. Targets 2008, 12:437-447.
28. Deierborg T., et al. Emerging restorative treatments for Parkinson's disease. Prog. Neurobiol. 2008, 85:407-432.
29. Peterson A.L., Nutt J.G. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 2008, 5:270-280.
30. Bjorklund T., Kordower J.H. Gene therapy for Parkinson's disease. Mov. Disord. 2010, 25(Suppl. 1):S161-S173.
31. Voutilainen M.H., et al. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. J. Neurosci. 2009, 29:9651-9659.
32. Dutta G., et al. The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam. Clin. Pharmacol. 2008, 22:453-464.
33. Glass C.K., et al. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
34. Xing B., et al. Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity. J. Neuroimmunol. 2010, 225:43-51.
35. Schober A., et al. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action. Neurobiol. Dis. 2007, 25:378-391.
36. Kowsky S., et al. RET signaling does not modulate MPTP toxicity but is required for regeneration of dopaminergic axon terminals. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:20049-20054.
37. Mijatovic J., et al. Constitutive Ret signaling is protective for dopaminergic cell bodies but not for axonal terminals. Neurobiol. Aging. 2009, 10.1016/j.neurobiolaging.2009.08.009.
38. Ries V., et al. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:18757-18762.
39. Kitada T., et al. Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice. J. Neurochem. 2009, 111:696-702.
40. Fusco D., et al. The RET51/FKBP52 complex and its involvement in Parkinson disease. Hum. Mol. Genet. 2010, 19:2804-2816.
41. Souza R.P., et al. Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia. Psychopharmacology 2010, 210:347-354.
42. Aron L., et al. Pro-survival role for Parkinson's associated gene DJ-1 revealed in trophically impaired dopaminergic neurons. PLoS Biol. 2010, 8:e1000349.
43. Chung C.Y., et al. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum. Mol. Genet. 2005, 14:1709-1725.
44. Burke R.E. Programmed cell death and new discoveries in the genetics of parkinsonism. J. Neurochem. 2008, 104:875-890.
45. Barker R.A. Continuing trials of GDNF in Parkinson's disease. Lancet Neurol. 2006, 5:285-286.
46. Barker R.A. Parkinson's disease and growth factors - are they the answer?. Parkinsonism. Relat. Disord. 2009, 15(Suppl. 3):S181-S184.
47. Bjorklund T., Kirik D. Scientific rationale for the development of gene therapy strategies for Parkinson's disease. Biochim. Biophys. Acta 2009, 1792:703-713.
48. Nutt J.G., et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60:69-73.
49. Gill S.S., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9:589-595.
50. Patel N.K., et al. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol. 2005, 57:298-302.
51. Slevin J.T., et al. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 2005, 102:216-222.
52. Lang A.E., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 2006, 59:459-466.
53. Hovland D.N., et al. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol. Pathol. 2007, 35:676-692.
54. Eberling J.L., et al. Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum. Gene. Ther. 2009, 20:511-518.
55. Eslamboli A., et al. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J. Neurosci. 2005, 25:769-777.
56. Eslamboli A., et al. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp. Neurol. 2003, 184:536-548.
57. Kirik D., et al. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 2000, 20:4686-4700.
58. Emborg M.E., et al. Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol. Dis. 2009, 36:303-311.
59. Lo Bianco C., et al. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiol. Dis. 2004, 17:283-289.
60. Herzog C.D., et al. Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol.Ther. 2008, 16:1737-1744.
61. Herzog C.D., et al. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery 2009, 64:602-612. discussion 612-603.
62. Kordower J.H., et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann. Neurol. 2006, 60:706-715.
63. Marks W.J., et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 2008, 7:400-408.
64. Marks W.J., et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010, doi:10.1016/S1474-4422(10)70254-44.
65. Vastag B. Biotechnology: crossing the barrier. Nature 2010, 466:916-918.
66. Behrstock S., et al. Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates. Gene. Ther. 2006, 13:379-388.
67. Biju K., et al. Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease. Mol. Ther. 2010, 18:1536-1544.
68. Lindvall O., Wahlberg L.U. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?. Exp. Neurol. 2008, 209:82-88.
69. Sajadi A., et al. Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease. Neurobiol. Dis. 2006, 22:119-129.
70. Kishima H., et al. Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons. Neurobiol. Dis. 2004, 16:428-439.
71. Gouhier C., et al. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease. Synapse 2002, 44:124-131.
72. Garbayo E., et al. Effective GDNF brain delivery using microspheres - a promising strategy for Parkinson's disease. J. Control Release 2009, 135:119-126.
73. Huang R., et al. Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. J. Gene. Med. 2009, 11:754-763.
74. Huang R., et al. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J. Neurol. Sci. 2010, 290:123-130.
75. Pardridge W.M., Boado R.J. Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. Pharm. Res. 2009, 26:2227-2236.
76. Xia C.F., et al. Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. J. Gene. Med. 2008, 10:306-315.
77. Bradley L.H., et al. Dopamine neuron stimulating actions of a GDNF propeptide. PLoS One 2010, 5:e9752.
78. Tokugawa K., et al. XIB4035, a novel nonpeptidyl small molecule agonist for GFRalpha-1. Neurochem. Int. 2003, 42:81-86.
79. Jang S.W., et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:2687-2692.
80. Saavedra A., et al. Driving GDNF expression: the green and the red traffic lights. Prog. Neurobiol. 2008, 86:186-215.
81. Weinreb O., et al. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann. N. Y. Acad. Sci. 2007, 1122:155-168.
82. Weinreb O., et al. Rasagiline; a novel anti-parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog. Neurobiol. 2010, 10.1016/j.pneurobio.2010.06.008.
83. Olanow C.W., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 2009, 361:1268-1278.
84. Parkinson Study Group A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 2004, 61:561-566.
85. Hauser R.A., et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov. Disord. 2009, 24:564-573.
86. Ahlskog J.E., Uitti R.J. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?. Neurology 2010, 74:1143-1148.
87. Olanow C.W., Rascol O. The delayed-start study in Parkinson disease: can't satisfy everyone. Neurology 2010, 74:1149-1150.
88. Visanji N.P., et al. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP1 in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J. 2008, 22:2488-2497.
89. Bishop N.A., et al. Neural mechanisms of ageing and cognitive decline. Nature 2010, 464:529-535.
90. Williams R. Slowing the decline. Nature 2010, 466:S13-14.
91. Krieglstein K. Factors promoting survival of mesencephalic dopaminergic neurons. Cell Tissue Res. 2004, 318:73-80.
92. Roussa E., et al. TGF-beta in dopamine neuron development, maintenance and neuroprotection. Adv. Exp. Med. Biol. 2009, 651:81-90.
93. von Bohlen und Halbach O., Unsicker K. Neurotrophic support of midbrain dopaminergic neurons. Adv. Exp. Med. Biol. 2009, 651:73-80.
94. Nagakubo D., et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem. Biophys. Res. Commun. 1997, 231:509-513.
95. Liou A.K., et al. Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway. Neurobiol. Dis. 2008, 32:116-124.
96. Vasseur S., et al. DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1111-1116.
97. Aleyasin H., et al. DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:3186-3191.
98. Seo J.H., et al. Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 2002, 16:1826-1828.
99. Fallon L., et al. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat. Cell Biol. 2006, 8:834-842.
100. Henn I.H., et al. Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J. Neurosci. 2007, 27:1868-1878.
101. Junn E., et al. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9691-9696.
102. Mo J.S., et al. DJ-1 modulates UV-induced oxidative stress signaling through the suppression of MEKK1 and cell death. Cell Death Differ. 2008, 15:1030-1041.
103. Ren Y., et al. Parkin protects dopaminergic neurons against microtubule-depolymerizing toxins by attenuating microtubule-associated protein kinase activation. J. Biol. Chem. 2009, 284:4009-4017.
104. Fan J., et al. DJ-1 decreases Bax expression through repressing p53 transcriptional activity. J. Biol. Chem. 2008, 283:4022-4030.
105. Giaime E., et al. Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6. Cell Death Differ. 2010, 17:158-169.
106. Opsahl J.A., et al. Increased interaction between DJ-1 and the Mi-2/nucleosome remodelling and deacetylase complex during cellular stress. Proteomics 2010, 10:1494-1504.
107. da Costa C.A., et al. Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat. Cell Biol. 2009, 11:1370-1375.
108. Ho C.C., et al. The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J. Neurosci. 2009, 29:1011-1016.
109. Iaccarino C., et al. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum. Mol. Genet. 2007, 16:1319-1326.
110. Tain L.S., et al. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat. Neurosci. 2009, 12:1129-1135.
111. Imai Y., et al. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 2008, 27:2432-2443.
112. Berger A.K., et al. Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. Hum. Mol. Genet. 2009, 18:4317-4328.
113. Plun-Favreau H., et al. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat. Cell Biol. 2007, 9:1243-1252.
114. Gandhi S., et al. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol. Cell 2009, 33:627-638.
115. Marongiu R., et al. Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux. J. Neurochem. 2009, 108:1561-1574.
116. Piltonen M., et al. Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Exp. Neurol. 2009, 219:499-506.
117. Manfredsson F.P., et al. Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol. Ther. 2009, 17:1857-1867.
118. Smith K. Treatment frontiers. Nature 2010, 466:S15-S18.